Analysts think MBRX stock price could increase by 676%
Jul 09, 2025, 11:26 AM
53.81%
What does MBRX do
Moleculin Biotech, a Houston-based clinical-stage pharmaceutical company, focuses on developing treatments for tumors and viruses with three core technologies and six drug candidates. Established in 2016, it employs 18 people and has candidates showing human activity in trials.
5 analysts think MBRX stock price will increase by 675.81%. The current median analyst target is $4.08 compared to a current stock price of $0.53. The lowest analysts target is $4.04 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
